Skip to main content

Kimyrsa FDA Approval History

Last updated by Judith Stewart, BPharm on April 1, 2021.

FDA Approved: Yes (First approved March 12, 2021)
Brand name: Kimyrsa
Generic name: oritavancin
Dosage form: for Injection
Company: Melinta Therapeutics
Treatment for: Skin and Structure Infection

Kimyrsa (oritavancin) is a lipoglycopeptide antibiotic for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSI) caused by designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA).

Development timeline for Kimyrsa

Mar 15, 2021Approval FDA Approves Kimyrsa (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.